Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin.
Title | Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. |
Publication Type | Journal Article |
Year of Publication | 2011 |
Authors | Cholongitas, E., Shusang V., Germani G., Tsochatzis E., Raimondo M. Luisa, Marelli L., Senzolo M., Davidson B. R., Patch D., Rolles K., & Burroughs A. K. |
Journal | Clin Transplant |
Volume | 25 |
Issue | 4 |
Pagination | 614-24 |
Date Published | 2011 Jul-Aug |
ISSN | 1399-0012 |
Keywords | Adolescent, Adult, Aged, Cohort Studies, Cyclosporine, Emulsions, Female, Follow-Up Studies, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Liver Transplantation, Male, Middle Aged, Postoperative Complications, Survival Rate, Tacrolimus, Time Factors, Treatment Outcome, Young Adult |
Abstract | BACKGROUND: Early withdrawal of steroids after liver transplantation has benefits, but rarely is total avoidance of steroids used. We evaluated long-term results of patients with ab initio monotherapy with cyclosporin (CYA) vs. tacrolimus (TAC), in randomized and cohort studies.METHODS: We evaluated long-term outcomes in 66 adults randomized to TAC or CYA and 94 subsequent patients who received TAC. Protocol liver biopsies were performed. Rejection was treated with three 1 g/d methylprednisolone. Further rejection after two courses of methylprednisolone was defined as monotherapy failure.RESULTS: Actuarial five-yr survival was 68% in TAC and 70% CYA. Monotherapy failed in 8% TAC and 13% CYA patients; no rejection in 24% TAC and 19% CYA patients; 42% TAC and 33% CYA patients were not exposed to any steroids. Rejection episodes were less with TAC, compared to CYA: mean 1.8 vs. 2.5, p = 0.042. Chronic rejection occurred in only 4 (11%) CYA patients. During follow-up of median 97 months (range: 0.06-145), there were 16 (44%) deaths in CYA and 48 (39%) in TAC patients (p > 0.05).CONCLUSIONS: TAC monotherapy ab initio is a viable immunosuppressive strategy in liver transplantation and was associated with lower rejection rates and renal complications, compared to CYA. |
DOI | 10.1111/j.1399-0012.2010.01321.x |
Alternate Journal | Clin Transplant |
PubMed ID | 20718824 |